Marco Ranzani

Marco Ranzani is an accomplished scientist with extensive experience in drug discovery and biology, currently serving as Associate Director and Senior Principal Scientist at Artios since November 2017. In this role, Marco leads the collaboration with Novartis to identify new drug targets and manages the Combination and Biomarker Validation Team, focusing on the study of proprietary compounds alongside traditional therapies. Previously, Marco held positions at the Wellcome Trust Sanger Institute and Telethon Institute for Gene Therapy, where significant contributions included the development of lentiviral vector platforms and identifying targeted therapies for melanoma. Marco's educational background includes degrees in Biotechnology from the Università degli Studi di Milano and ongoing studies at the University of Cambridge.